Grants and Contributions:
Title:
Preclinical development and tox studies for biologic treating diabetic macular edema.
Agreement Number:
985236
Agreement Value:
$491,493.00
Agreement Date:
Dec 23, 2021 - Oct 31, 2023
Description:
Development of analytical methods allowing to determine the tolerability, pharmacokinetics and pharmacodynamics of various treatments under development for retinopathy. The results will allow the selection of the molecule continuing their developments towards the next stages of the IND-enabling preclinical studies.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Westmount, Quebec, CA H3Z 2S6
Reference Number:
172-2021-2022-Q4-985236
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
748799525
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 179 days.
Amendment Date
Jul 19, 2023
Recipient's Legal Name:
Semathera Inc.
Federal Riding Name:
Notre-Dame-de-Grâce--Westmount
Federal Riding Number:
24053
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: